Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2016 1
2017 1
2019 3
2020 5
2021 1
2023 2
2024 2
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents.
Edvardsson CE, Zhang X, Emous TA, Adermark L, Witley S, Ericson M, Schmidt HD, Jerlhag E. Edvardsson CE, et al. Among authors: schmidt hd, jerlhag e. EBioMedicine. 2026 Apr;126:106219. doi: 10.1016/j.ebiom.2026.106219. Epub 2026 Mar 23. EBioMedicine. 2026. PMID: 41875498 Free PMC article.
METHODS: Here we investigated whether tirzepatide, a clinically approved long-acting dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist, alters cocaine-related behavioural and neurochemical response …
METHODS: Here we investigated whether tirzepatide, a clinically approved long-acting dual glucose-dependent insulinotropic polypeptide (GIP) …
Characterizing ghrelin's role in dysregulating GLP-1-mediated function and promoting the development of alcohol-associated liver disease.
Mahalingam S, Bellamkonda R, Kharbanda KK, Ethiraj O, Nagarajan N, Guda C, Sharma K, Schott MB, Casey CA, Leggio L, Rasineni K. Mahalingam S, et al. Among authors: leggio l. Biomed Pharmacother. 2026 Feb;195:118924. doi: 10.1016/j.biopha.2025.118924. Epub 2026 Jan 12. Biomed Pharmacother. 2026. PMID: 41518733 Free PMC article.
This study investigated the complex interplay between two gut hormones, glucagon-like peptide-1 (GLP-1) and ghrelin and their role in the development of alcohol-associated liver disease (ALD). ...Chronic ethanol feeding in wildtype rat …
This study investigated the complex interplay between two gut hormones, glucagon-like peptide-1 (GLP-1) and ghre …
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
Edvardsson CE, Adermark L, Gottlieb S, Alfreji S, Emous TA, Gouda Y, Thorsell A, Vujičić M, Aranäs C, Benrick A, Wernstedt Asterholm I, Lopez MF, Becker HC, Jerlhag E. Edvardsson CE, et al. Among authors: jerlhag e. EBioMedicine. 2026 Feb;124:106119. doi: 10.1016/j.ebiom.2025.106119. Epub 2026 Jan 7. EBioMedicine. 2026. PMID: 41506148 Free PMC article.
METHODS: Here, we examined the effects of tirzepatide, a long-acting dual glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist approved for diabetes and obesity, using behavioural assays (lo …
METHODS: Here, we examined the effects of tirzepatide, a long-acting dual glucagon-like peptide-1 receptor (GLP- …
Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.
Aranäs C, Caffrey A, Edvardsson CE, Schmidt HD, Jerlhag E. Aranäs C, et al. Among authors: schmidt hd, jerlhag e. Eur Neuropsychopharmacol. 2025 Sep;98:1-10. doi: 10.1016/j.euroneuro.2025.07.001. Epub 2025 Jul 10. Eur Neuropsychopharmacol. 2025. PMID: 40644799 Free article.
Currently, no pharmaceutical treatments exist for cocaine use disorder, which is characterized by dysregulated motivation, intense drug craving, compulsive drug-seeking behavior, and relapse during abstinence. While short-acting glucagon-like peptide-1 …
Currently, no pharmaceutical treatments exist for cocaine use disorder, which is characterized by dysregulated motivation, intense drug crav …
An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents.
Edvardsson CE, Cadeddu D, Ericson M, Adermark L, Jerlhag E. Edvardsson CE, et al. Among authors: jerlhag e. EBioMedicine. 2025 May;115:105684. doi: 10.1016/j.ebiom.2025.105684. Epub 2025 Apr 17. EBioMedicine. 2025. PMID: 40245495 Free PMC article.
Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as potential AUD treatment, as they have been shown to modulate reward-related behaviours, including those linked to alcohol consumption. ...FINDINGS: LS GLP-1R activation attenuate …
Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as potential AUD treatment, as they have been sh …
Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.
Farokhnia M, Tazare J, Pince CL, Bruns N 6th, Gray JC, Lo Re V 3rd, Fiellin DA, Kranzler HR, Koob GF, Justice AC, Vendruscolo LF, Rentsch CT, Leggio L. Farokhnia M, et al. Among authors: leggio l. J Clin Invest. 2025 Mar 6;135(9):e188314. doi: 10.1172/JCI188314. eCollection 2025 May 1. J Clin Invest. 2025. PMID: 40048376 Free PMC article.
We further tested the effects of 2 DPP-4Is, linagliptin and omarigliptin, on binge-like alcohol drinking in mice and operant oral alcohol self administration in alcohol-dependent rats, models previously used to show a significant effect of the G …
We further tested the effects of 2 DPP-4Is, linagliptin and omarigliptin, on binge-like alcohol drinking in mice and operant o …
The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats.
Aranäs C, Edvardsson CE, Zentveld L, Vallöf D, Witley S, Tufvesson-Alm M, Shevchouk OT, Vestlund J, Jerlhag E. Aranäs C, et al. Among authors: jerlhag e. Acta Neuropsychiatr. 2024 Dec 6;37:e42. doi: 10.1017/neu.2024.58. Acta Neuropsychiatr. 2024. PMID: 39639536
While the combination of amylin receptor (AMYR) and glucagon-like peptide-1 receptor (GLP-1R) agonists have been found to decrease feeding and body weight in obese male rats synergistically, their combined impact on alcohol intake is unkn …
While the combination of amylin receptor (AMYR) and glucagon-like peptide-1 receptor (GLP-1R) agonists have been …
Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.
Aranäs C, Caffrey A, Edvardsson CE, Vestlund J, Schmidt HD, Jerlhag E. Aranäs C, et al. Among authors: schmidt hd, jerlhag e. Br J Pharmacol. 2025 Mar;182(6):1292-1305. doi: 10.1111/bph.17406. Epub 2024 Dec 2. Br J Pharmacol. 2025. PMID: 39622492 Free article.
BACKGROUND AND PURPOSE: The limited effectiveness of current pharmacological treatments for alcohol use disorder (AUD) highlights the need for novel therapies. These may involve the glucagon-like peptide-1 receptor or the amylin receptor, as tre …
BACKGROUND AND PURPOSE: The limited effectiveness of current pharmacological treatments for alcohol use disorder (AUD) highlights the …
Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.
Aranäs C, Blid Sköldheden S, Jerlhag E. Aranäs C, et al. Among authors: jerlhag e. Front Pharmacol. 2023 Aug 31;14:1180512. doi: 10.3389/fphar.2023.1180512. eCollection 2023. Front Pharmacol. 2023. PMID: 37719854 Free PMC article.
Preclinical studies have identified glucagon-like peptide-1 receptor (GLP-1R) agonists, and the antismoking agents varenicline and bupropion as tentative agents for treatment of alcohol use disorder (AUD). ...Successfully, this approach has been …
Preclinical studies have identified glucagon-like peptide-1 receptor (GLP-1R) agonists, and the antismoking agen …
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. Chuong V, et al. Among authors: leggio l. JCI Insight. 2023 Jun 22;8(12):e170671. doi: 10.1172/jci.insight.170671. JCI Insight. 2023. PMID: 37192005 Free PMC article.
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD). ...Semaglutide also reduced binge …
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of ad …
20 results